IDE Cybersecurity

FDA Investigational Device Exemption (IDE) submissions sit on a 30-day review clock and are evaluated under 21 CFR Part 812. Section 524B does not reach an IDE - it enumerates 510(k), De Novo, PMA, PDP, and HDE - but 21 CFR 812.25 is binding regulation, and the February 3, 2026 premarket cybersecurity guidance still describes what reviewers expect. Inadequate cybersecurity evidence can trigger a Clinical Hold under 21 CFR 812.42 that stops enrollment until concerns are resolved. This hub pulls together the services, guides, standards, and FAQs that explain what an IDE-scoped cybersecurity package looks like - and how to build it so the artifacts roll forward into the eventual 510(k), De Novo, or PMA.

Services

• Full-Service FDA Premarket Cybersecurity

  Full-service, end-to-end: we deliver 100% of the artifacts FDA reviewers expect for 510(k), De Novo, PMA, PDP, and HDE submissions under §524B, plus IDE applications under 21 CFR 812 and the FDA's February 3, 2026 premarket guidance - traceable, complete, and current.

• Medical Device Threat Modeling

  Comprehensive threat modeling per FDA Section V.A.1 - covering supply chain, deployment, environment of use, and decommission risks for the full device system.

• Medical Device Penetration Testing

  Hardware, firmware, mobile, and cloud - tested by operators with both red-team and medical-device experience. Reports built for FDA reviewers.

• FDA-Compliant SBOM Services

  Machine- and human-readable SBOMs with NTIA minimum elements (now stewarded by CISA), vulnerability mapping, and end-of-support tracking - built for FDA review.

In-depth guides

• IDE Cybersecurity Requirements: The Investigational Device Guide (2026)What cybersecurity documentation an IDE application needs under 21 CFR 812 and the FDA February 3, 2026 premarket guidance, and why Section 524B does not apply.
• IDE Cybersecurity Submission GuideAssemble the cybersecurity content of an IDE application: Appendix 3's five elements, the binding 21 CFR 812.25 requirements behind them, and risk-scaled documentation breadth.
• FDA Pathway Cybersecurity Differences: 510(k), De Novo, PMA, HDE, IDE, Q-Sub, PDPHow cybersecurity expectations differ across FDA pathways - 510(k), De Novo, PMA, HDE, IDE, Q-Sub, and PDP - under Section 524B and the February 2026 final guidance.
• 12 Critical Threat-Modeling Gaps in SubmissionsA practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
• The SPDF PlaybookA practical, ungated guide to building a Secure Product Development Framework (SPDF) that FDA accepts, the eight pillars, the artifacts each one produces, and a pre-submission readiness checklist you can score yourself against.
• The MedTech Cybersecurity Standards DecoderA plain-English field guide to FDA Section 524B, IEC 81001-5-1, AAMI TIR57, ANSI/AAMI SW96, ISO 14971, and 8 more medical device cybersecurity standards, what they require, how they connect, and what FDA expects in your eSTAR premarket submission.

Standards & guidance

Defined entries from our MedTech Cybersecurity Standards Glossary.

• FDA 2026 GuidanceFDA Premarket Cybersecurity Guidance (Feb 3, 2026)The FDA's final premarket cybersecurity guidance, effective February 3, 2026. Defines the seven-section cybersecurity submission format reviewers now enforce at Technical Screening, replacing the 2023 draft. Operationalizes Section 524B of the FD&C Act.
• Section 524BFD&C Act Cyber Device RequirementsSection 524B of the FD&C Act (the statutory partner to 21 CFR 807.81) was added by the Consolidated Appropriations Act, 2023. It gives the FDA explicit authority to require a complete cybersecurity package in every premarket submission for a cyber device, and to refuse submissions that lack one. It works alongside 21 CFR 807.81, which sets the 90-day 510(k) filing floor.
• ANSI/AAMI SW96Medical Device Security Risk ManagementThe consensus standard for medical device security risk management - asset, threat, vulnerability, likelihood, severity, and residual risk acceptability.
• AAMI TIR57Principles for Medical Device Security - Risk ManagementThe MedTech-specific extension of ISO 14971 for cybersecurity. Defines how to identify cybersecurity assets, threats, and vulnerabilities, then estimate, evaluate, and control the resulting risk.
• ISO 14971Medical Device Risk ManagementThe umbrella risk-management standard for medical devices. Defines hazard identification, risk estimation, risk evaluation, risk control, and residual risk evaluation. Cybersecurity risks must be reconciled here so a security control never silently introduces a safety hazard.
• SPDFSecure Product Development FrameworkA documented framework that shows security activities are integrated across the device lifecycle - not bolted on at the end. Includes secure requirements, threat modeling, secure coding, V&V, vulnerability management, and post-market response.

From the blog

• FDA IDE Cybersecurity Requirements: 2026What the FDA's Feb 2026 guidance recommends for IDE cybersecurity: informed consent, architecture views, SBOM, labeling, and what's not required yet.
• Threat Modeling Connected & Implantable DevicesA short orientation to threat modeling connected and implantable medical devices, with a pointer to the full STRIDE pillar guide for FDA-ready methodology.
• Medical Device Safety vs Security RisksExplore the critical distinctions between safety and security risks in medical devices. Aligned with the FDA's Feb 3, 2026 premarket cybersecurity guidance.
• Cybersecurity Best Practices for DevicesDiscover cybersecurity best practices for medical device design, from threat modeling to FDA-aligned lifecycle management, to protect patients and data.

Interactive tools

• Pathway crosswalk

  Compare what IDE, 510(k), De Novo, and PMA each expect on cybersecurity evidence.

Related FDA deficiencies

The deficiency letters reviewers most often write on submissions in this topic area. Each links to the full response playbook.

• Insufficient Penetration Testing Evidence

  Reviewers find your penetration test scope too narrow, methodology unclear, or testers insufficiently independent.

  Response playbook
• Insufficient Secure Boot Evidence

  Reviewers want test evidence that secure boot, signed updates, and root-of-trust controls function as claimed.

  Response playbook
• Incomplete Threat Model

  Reviewers say your STRIDE/attack-tree analysis misses interfaces, trust boundaries, or post-market threat surfaces.

  Response playbook
• Missing Security Architecture Views

  Your submission is missing one or more of the architecture views FDA 2026 expects (global system, multi-patient, updateability).

  Response playbook

Related topics

Adjacent hubs in the same regulatory lifecycle, with the guides, articles, tools, and questions they cover that this hub does not.

• 510(k) CybersecurityShares FDA 2026 Guidance, Section 524B, ANSI/AAMI SW96 · Same service track: Full-Service FDA Premarket Cybersecurity

  A 510(k) cybersecurity package for a cyber device includes the SPDF narrative, threat model, security risk assessment tied to ISO 14971, machine-readable SBOM with VEX, security architecture views, penetration and vulnerability testing evidence, postmarket monitoring plan with coordinated vulnerability disclosure, and cybersecurity labeling.

  • FDA Premarket Cybersecurity Submission Checklist GuideGuideEnsure your 510(k) or PMA is compliant. Use our checklist for FDA premarket cybersecurity submissions, covering SBOM, threat models, and pen testing.
  • 510(k) Cybersecurity Requirements Every Maker Must MeetArticleFDA 510(k) cybersecurity requirements - threat model, SBOM, testing, postmarket plan - scaled across 510(k), De Novo, and PMA pathways under Section 524B.
  • SIR response builderToolDraft a structured cybersecurity response to a Submission Issue Request, section by section, before the clock runs out.

  How is 510(k) cybersecurity different from De Novo or PMA?

  The seven-section cybersecurity package the FDA expects is the same across 510(k), De Novo, and PMA - the differences are scope and depth. 510(k) reviewers focus heavily on substantial equivalence to a predicate, so the threat model and risk assessment have to show that any new connectivity, software, or interfaces don't change the safety profile in a way the predicate didn't address. PMA goes further on manufacturing and quality-system evidence; De Novo allows special controls that can include cybersecurity-specific requirements.

  More 510(k) Cybersecurity FAQs
• MedTech Cybersecurity StandardsShares FDA 2026 Guidance, Section 524B, ANSI/AAMI SW96 · Same service track: Full-Service FDA Premarket Cybersecurity

  The standards MedTech teams actually need are a short list: ISO 14971 for safety risk management, ANSI/AAMI SW96:2023 for security risk management, AAMI TIR57 as its predecessor and companion, IEC 62304 for software lifecycle, IEC 81001-5-1 for secure development, and UL 2900 series where a certification is contractually required.

  • EU MDR vs FDA Medical Device Cybersecurity: A Side-by-Side CrosswalkGuideHow EU MDR/IVDR cybersecurity requirements compare to FDA Section 524B and the February 2026 guidance - Annex I §17.2, MDCG 2019-16, SBOM, vulnerability handling, and postmarket obligations.
  • AAMI TIR57 Risk Management for Medical DevicesArticle
  • EU AI Act vs FDA AI/ML Cybersecurity for DevicesGuideHow EU AI Act Article 15 obligations compare to the FDA's PCCP framework and Section 524B for AI/ML SaMD.

  Which standards does the FDA actually require?

  The FDA requires compliance with statute (Section 524B) and 21 CFR Part 820 / QMSR. They recognize - but don't strictly mandate - consensus standards like AAMI SW96, IEC 81001-5-1, and ISO 14971. In practice, declaring conformance to those standards is the cleanest path through review.

  More MedTech Cybersecurity Standards FAQs
• PMA CybersecurityShares FDA 2026 Guidance, Section 524B, ANSI/AAMI SW96 · Same service track: Full-Service FDA Premarket Cybersecurity

  PMA cybersecurity is the same Section 524B content set as any other pathway, applied at greater depth because Class III devices are life-sustaining or life-supporting.

  • FDA PMA Cybersecurity Requirements: Expert Guide (2024)GuideMaster FDA PMA cybersecurity requirements. Learn the technical documentation, risk management, and SPDF requirements needed for a successful Class III submissio
  • FDA Cybersecurity Deficiencies TriggersArticleUnderstanding what causes the FDA to issue a cybersecurity deficiency for medical devices starts with one uncomfortable truth: most deficiencies have.
  • eSTAR cybersecurity checklistToolWalk the cybersecurity sections your PMA package has to fill before the acceptance screen.

  How is PMA cybersecurity different from a 510(k)?

  PMA cybersecurity packages go deeper on every section. Threat models cover safety-critical clinical scenarios end-to-end, not just connected interfaces; pen testing typically includes white-box review of safety-critical firmware paths; the postmarket plan must defend the device through its full intended lifetime, not just the next clearance cycle. Reviewers also issue more cybersecurity deficiencies on PMAs than on any other pathway, so the bar for evidence quality is higher.

  More PMA Cybersecurity FAQs

Get FDA cleared without the cybersecurity headaches.

30-minute strategy session. No cost, no commitment - just answers from people who've shipped 250+ FDA submissions.